Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vivani Medical (VANI)
NASDAQ:VANI
Holding VANI?
Track your performance easily
VANI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.84 - $7.80
Previous Close$1.33
Volume87.53K
Average Volume (3M)384.09K
Market Cap
$73.67M
Enterprise Value$73.16M
Total Cash (Recent Filing)$20.65M
Total Debt (Recent Filing)$20.70M
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Aug 12, 2024EPS Estimate
-$0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding50,726,329
10 Day Avg. Volume68,671
30 Day Avg. Volume384,094
Standard Deviation0.55
R-Squared0.06
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-31.89
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-9.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.75
Forecast
1Y Price Target
$8.00Price Target Upside501.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Vivani Medical News
PremiumCompany Announcements
Vivani Medical Reports Q3 Loss, Advances GLP-1 Trials
PremiumCompany Announcements
Vivani Medical Secures Funding for GLP-1 Implant Trial
PremiumCompany Announcements
Vivani Medical’s Regular Industry Conference Presentations UpdateBulls Say, Bears Say
Bulls Say
Market PotentialThe GLP-1 class and obesity market is a blockbuster opportunity with the potential to address multiple metabolic diseases, and existing products are experiencing shortages, indicating a significant market potential for a 6-month GLP-1 implant.
Product AdvantagesNPM-115, a twice yearly implant, demonstrated 20% weight loss in a pre-clinical mice model, showing promise for treating obesity with a profile similar to the successful semaglutide.
Regulatory ApprovalThe FDA cleared its Investigational New Drug Application (IND) for NPM-119 and removed the clinical hold.
Bears Say
Regulatory IssuesVANI received verbal notification from the FDA that the IND for NPM-119 will be placed on clinical hold due to insufficient CMC information, requiring a response to lift the hold.
Regulatory NotificationsOn 8/11/23, VANI received verbal notification from the FDA that the IND for NPM-119 will be placed on clinical hold.
Strategic FocusNPM-119 is no longer a strategic focus as VANI is shifting to prioritizing the development of NPM-115.
---
Ownership Overview
88.20% Insiders
1.93% Mutual Funds
9.49% Other Institutional Investors
0.38% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
VANI FAQ
What was Vivani Medical’s price range in the past 12 months?
Vivani Medical lowest stock price was $0.84 and its highest was $7.80 in the past 12 months.
What is Vivani Medical’s market cap?
Currently, no data Available
When is Vivani Medical’s upcoming earnings report date?
Vivani Medical’s upcoming earnings report date is Aug 12, 2024 which is 107 days ago.
How were Vivani Medical’s earnings last quarter?
Vivani Medical released its earnings results on May 13, 2024. The company reported -$0.12 earnings per share for the quarter, the consensus estimate of -$0.12 by $0.
Is Vivani Medical overvalued?
According to Wall Street analysts Vivani Medical’s price is currently Undervalued.
Does Vivani Medical pay dividends?
Vivani Medical does not currently pay dividends.
What is Vivani Medical’s EPS estimate?
Vivani Medical’s EPS estimate is -$0.12.
How many shares outstanding does Vivani Medical have?
Vivani Medical has 54,978,466 shares outstanding.
What happened to Vivani Medical’s price movement after its last earnings report?
Vivani Medical reported an EPS of -$0.12 in its last earnings report, expectations of -$0.12. Following the earnings report the stock price went down -1.081%.
Which hedge fund is a major shareholder of Vivani Medical?
Currently, no hedge funds are holding shares in VANI
---
Vivani Medical Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (501.50% Upside)
$8.00 (501.50% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.87%
12-Months-Change
Fundamentals
Return on Equity
-75.65%
Trailing 12-Months
Asset Growth
20.66%
Trailing 12-Months
Company Description
Vivani Medical
Second Sight Medical Products, Inc. engages in the development, manufacture, and marketing of implantable visual prosthetics. Its product, the Argus II Retinal Prosthesis System, treats outer retinal degenerations, such as retinitis pigmentosa, also referred to as RP. The company was founded by Alfred E. Mann, Aaron Mendelsohn, Sam Williams, Robert J. Greenberg, and Gunnar Bjorg in 1998 and is headquartered in Sylmar, CA.
---
VANI Stock 12 Month Forecast
Average Price Target
$8.00
▲(501.50% Upside)
Technical Analysis
Best Analysts Covering VANI
1 Year
1 Year Success Rate
4/7 ratings generated profit
1 Year Average Return
-0.70%
reiterated a buy rating 5 months ago
Copying Naz Rahman's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of -0.70% per trade.
---